Research Commitment Elevating UConn s Internal Medicine Residency uconn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uconn.edu Daily Mail and Mail on Sunday newspapers.
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress - read this article along with other careers information, tips and advice on BioSpace
Life of Young Mom with Sickle Cell Disease Improved by New Drug
Patients at UConn Health s New England Sickle Cell Institute have a range of advanced health management options available to them
Brandy Compton, with her son Jermaine (contributed photo). Copy Link
Since she was only 4 months old, Brandy Compton, 31, of Hartford, has been battling sickle cell disease, a painful inherited red blood cell condition impacting the blood’s circulation due to abnormally hook-shaped red blood cells.
“As a baby I wouldn’t stop crying, and nothing my mother did worked to console me. Then they found out I had sickle cell disease,” says Compton. “Growing up was challenging, and I was homeschooled after the third grade since I was missing way too many days of school due to my painful disease.”
Imara reports Phase 2a clinical trial results of -2- finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(2)
DJ Imara reports Phase 2a clinical trial results of IMR-687 in adult patients with sickle cell disease
Arix Bioscience PLC (ARIX)
Imara reports Phase 2a clinical trial results of IMR-687 in adult patients
with sickle cell disease
06-Jan-2021 / 14:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement. Arix Bioscience plc Imara reports Phase 2a clinical trial results of IMR-687 in adult patients with sickle cell disease LONDON, 06 January 2021: Arix Bioscience plc ( Arix , LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Imara Inc. (Nasdaq: